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Abstract 
 
Aims: The aims of this study were to evaluate the role of free fatty acid receptor 2 (FFAR2/GPR43) in 
mediating the effects of the short chain fatty acids (ScFAs) sodium acetate (SA) and sodium propionate 
(SP) on islet function in vitro, and to identify the intracellular signalling pathways utilised in ScFA-
induced potentiation of glucose-induced insulin secretion. 
Material and methods: Islets of Langerhans were isolated from WT and FFAR2-/- mice and from non-
diabetic human donors. The effects of SA and SP on dynamic insulin secretion from perifused islets 
were quantified by radioimmunoassay, signalling downstream of ScFAs was profiled by single-cell 
calcium microfluorimetry, and measurement of cAMP by fluorescence assay. Islet apoptosis was 
induced by exposure to cytokines or sodium palmitate and the effects of SA and SP to regulate islet 
apoptosis were assessed by quantification of caspase 3/7 activities. 
Results: Deletion of FFAR2 did not affect islet morphology or insulin content. SA and SP reversibly 
potentiated insulin secretion from mouse islets in a FFAR2-dependent manner. ScFA-induced 
potentiation of insulin secretion was coupled to Gq activation of phospholipase C and protein kinase 
C, with no evidence of Gi-mediated signalling. SA and SP protected human and mouse islets from 
apoptosis and these pro-survival properties were dependent on islet expression of FFAR2. 
Conclusions: Our results indicate that FFAR2 directly mediates both the stimulatory effects of SA and 
SP on insulin secretion and their protection against islet apoptosis. We have also shown that ScFA 
coupling in islets occurs via Gq-coupled intracellular signalling.  
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Introduction 
Diet-derived short-chain fatty acids (ScFAs) originate from the intestinal fermentation of fibre and 
undigested carbohydrates by bacteria residing in the colonic lumen [1]. They consist of fatty acid 
chains of up to 6 carbons, with acetate (C2), propionate (C3) and butyrate (C4) representing the main 
circulating forms in the human body [2]. In recent years it has become apparent that ScFAs are the 
endogenous ligands for two G-protein coupled receptors, namely FFAR2 (GPR43) and FFAR3 (GPR41) 
[3], and that these receptors are expressed in organs playing a role in glucose homeostasis. In 
particular, we and others have identified that FFAR2 and FFAR3 are expressed by islets of Langerhans 
[4-7], opening up the possibility that ScFAs contribute to the regulation of insulin secretion through 
activation of these receptors. However, the data published so far do not provide a consensus role for 
ScFAs and their receptors in islets: the first paper published in this area reported that acetate inhibited 
insulin release in vitro and that deletion of FFAR2 and FFAR3 improved glucose tolerance [7], while 
there have been more recent reports of ScFAs stimulating insulin secretion and deletion of FFAR2 
being associated with insufficient -cell mass expansion in obesity and gestational diabetes [5, 6, 8-
12]. Acetate is the most abundant circulating ScFA, reaching plasma concentrations of approximately 
200M [13], while propionate concentrations are approximately 10-fold lower [2], and these are the 
two ScFAs that are used most commonly for experimental studies. They can couple to both inhibitory 
and stimulatory signalling through activation of FFAR2 and/or FFAR3, which differ in their downstream 
signalling cascades [3, 14]. Thus, while FFAR3 couples only to Gi to decrease intracellular cyclic AMP 
levels, FFAR2 is able to recruit both Gi and Gq to decrease cyclic AMP and increase diacylglycerol and 
inositol trisphosphate generation. We have previously demonstrated that cannabinoid receptor 
agonists that signal through both Gi and Gq increase insulin secretion, as the stimulatory input 
outweighs the reduction in cyclic AMP production [15,16], and it has recently been reported that a 
Gq-biased FFAR2-selective agonist potentiates glucose-induced insulin secretion [12]. Consistent with 
this, we have reported that propionate reversibly stimulates insulin secretion from human islets 
through a Gq/protein kinase C-dependent pathway [5].  
4 
 
 
Observations of stimulatory signalling in -cells via FFAR2 contrast with the report that transgenic 
mice with global FFAR2 deletion show enhanced insulin secretion, which implicates pre-eminence of 
the Gi signalling pathway in mouse -cells [7]. In the current paper we have used islets isolated from 
wildtype and FFAR2-/- mice to quantify the effects of acetate and propionate on dynamic insulin 
secretion and determine the roles of intracellular calcium and PKC activation in ScFA signalling in 
mouse islets. We have also determined whether ScFAs can protect mouse islets from apoptosis 
induced by lipo- and cyto-toxic assault, and the role of FFAR2 in this. Key experiments exploring the 
role of acetate on insulin secretion and islet survival were also carried using isolated human islets.  
 
MATERIAL AND METHODS 
Materials 
Culture media and supplements, general laboratory chemicals and genotyping primers were from 
Merck (Dorset, UK); tissue culture flasks, coverslips and ThermoPrime 2x ReddyMix PCR Master Mix 
were from Thermo Fisher Scientific (Paisley, UK); Cell Titer-Glo 3D assay and Caspase3/7 Glo assay 
were from Promega (Hampshire, UK); cyclic AMP HiRange assay was from Cisbio (Codolet, France); 
TNFα, IL-1β and IFN were from PeproTech (London, UK); the high capacity reverse transcriptase kit 
was from Applied Biosystems (Woolston, UK) and RNeasy RNA extraction kits and Quantitect qPCR 
primers were from Qiagen (Manchester, UK). Anti-insulin, anti-glucagon and anti–somatostatin 
antibodies were from DAKO (Cambridge, UK) and Alexa-fluor secondary antibodies were from GE 
Healthcare Life Sciences (Little Chalfont, UK).  
 
Mice 
All animal procedures were approved by the UK Home Office Animals (Scientific Procedures) Act 1986 
(project licence number: 70/8068). FFAR2 global knockout (FFAR2-/-) mice were obtained from 
Professor McKay at the Garven Institute, Australia. FFAR2 deletion in C57Bl/6J mice was obtained by 
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homologous recombination which substitutes a 55bp of Ffar2 exon 1 with the β-gal-neo cassette, 
shifting the downstream amino acid sequence out of the reading frame and the progenies were 
generated through cross breeding of mice heterozygous for FFAR2 (FFAR2+/-). Genotypes of offspring 
were determined by standard PCR as described earlier [17]. All mice were housed at 21-23°C on a 12h 
light/dark cycle at Imperial College London, with food and water provided ad libitum. 
 
Islet isolation 
Islets were isolated from FFAR2-/- mice (aged 8-10 weeks) and age-matched wildtype (WT) mice, 
essentially as described [18]. Islets were maintained overnight at 37°C in RPMI supplemented with 
10% FBS, 2mM glutamine and 100U/mL/0.1mg/mL penicillin/streptomycin. Human islets were 
isolated from the pancreases of seventeen non-diabetic donors (BMI: 28.8±1.3; donor age: 41.6±3.1 
years; 8M, 9F) at the King’s College Hospital Islet Transplantation Unit, with appropriate ethical 
approval (LREC 01-082) [19] and maintained for up to 48 hours in CMRL supplemented with 2% human 
albumin, 4mM glutamine, 2mM HEPES (pH 7.2-7.4), and 10mM nicotinamide. When used for mRNA 
extraction, islets were snap frozen in liquid nitrogen immediately after isolation. 
 
Quantification of FFAR3 mRNA expression 
Total RNA was extracted from groups of 200 islets isolated from either WT or FFAR2-/- mice using the 
Qiagen RNeasy Minikit [4], then mRNA was reverse-transcribed into cDNA, which was quantified using 
a NanoDrop spectrophotomoter. Quantitative PCR reactions were performed on a Lightcycler 480 
using 1μg of cDNA and specific primers for FFAR3, and expression levels were normalised to Gapdh 
mRNA expression in the same samples [4]. 
 
Fluorescence immunohistochemistry 
5μm sections of paraffin-embedded fixed pancreases from WT or FFAR2-/- mice were boiled in 0.01M 
citric acid buffer (pH 6.0) for 2.5 minutes for antigen retrieval, blocked with 0.1% donkey serum in 
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PBS/0.02% triton X-100 for 1 hour then incubated at 4°C overnight with guinea pig anti-insulin (1:250), 
rabbit anti-glucagon (1:250) and rabbit anti-somatostatin (1:250) antibodies. Sections were exposed 
to Alexa-fluor secondary antibodies (1:250) for 1 hour at room temperature and fluorescence images 
were acquired using a Nikon Eclipse TE2000-U microscope. 
 
Insulin secretion and content 
Groups of 40 mouse or 50 human islets were perifused at 0.5mL/min with a physiological salt solution 
[20] supplemented with agents of interest and perifusate samples were collected every two minutes 
for quantification of secreted insulin [21]. In some experiments islet PKC was down-regulated by 
maintenance of islets for 20 hours in the presence of 200nM 4β phorbol 12-myristate 13-acetate 
(PMA) and control islets were treated with the inactive phorbol ester 4α phorbol 12,13 didecanoate 
(PDD) [22], and in other experiments islets were exposed to 100ng/mL of pertussis toxin (PTX) for 18 
hours to block Gi-dependent signalling [23]. For measurements of insulin content, groups of 10 islets 
were sonicated in 100L of acidified ethanol (absolute ethanol: deionised water: concentrated HCl in 
the ratio of 52:17:1v/v) and insulin was quantified by radioimmunoassay following 1/10,000 dilution 
of samples in assay buffer [21]. 
 
Calcium microfluorimetry 
Groups of 100,000 mouse islet cells adherent on UV-sterilised acetic acid-washed glass coverslips were 
incubated for 15 minutes with 5μM Fura-2 AM. The coverslips were placed in a steel chamber on a 
heating platform and cells were perifused with a physiological salt solution [20] containing test agents. 
Real-time changes in [Ca2+]i were determined by illuminating cells alternately at 340nm and 380nm, 
and light emitted from groups of cells in the field of view with a x20 objective was filtered at 510nm 
and recorded with a CCD camera [21]. 
 
Cyclic AMP quantification 
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Groups of 5 mouse or human islets were incubated for 1 hour at 37°C in a physiological salt solution 
[20] containing test agents of interest and supplemented with 2mM IBMX to inhibit 
phosphodiesterases. Islets were lysed and cAMP levels were quantified using a fluorescence assay, 
according to the manufacturer’s instructions. Data were acquired using a PHERAstar FS microplate 
reader (100μs delay time, 100μs integration time, 50 flash read time). 
 
ATP generation 
Groups of 3 islets were incubated for 1 hour at 37°C and ATP levels were determined by 
chemoluminescence with the Promega® 3D Cell Titer-Glo assay, according to the manufacturer’s 
instructions [24]. 
 
Apoptosis 
Mouse or human islets were pre-cultured in complete medium in the absence or presence of 
propionate or acetate for 24h, then groups of 5 islets were exposed to RPMI with 2% FBS (mouse) or 
CMRL with 0.2% albumin (human) supplemented either with 0.5mM sodium palmitate or a cytokine 
cocktail (5U/μl TNFα, 0.5U/μl IL-1β, 5U/μl IFN) in the continued absence or presence of acetate or 
propionate for a further 20h. Palmitate was initially made as a 100mM stock in 50% ethanol, diluted 
to 5mM in 10% fatty acid-free BSA in RPMI, then further diluted in RPMI (2% FBS) to 0.5mM for 
experimental use. Islet cell apoptosis was determined using the Caspase3/7 Glo assay according to 
the manufacturer’s instructions [5]. In this assay activation of the effector caspases 3 and 7 leads to 
cleavage of a proluminescent substrate, resulting in generation of a luminescent signal that was 
quantified using a Veritas luminometer at 450nm. 
 
Statistical Analysis 
Static incubation data were analysed with Prism® Graphpad using one way ANOVA followed by Dunnet 
multiple comparison test or Student’s t-tests, as appropriate. Perifusion secretion data were analysed 
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by one or two way ANOVA with repeated measures. Differences were considered statistically 
significant when p<0.05. 
 
RESULTS 
FFAR2 deletion does not impair mouse islet physiological parameters. 
Immunohistochemical analysis of pancreas sections indicated that global deletion of FFAR2 did not 
have any effect on islet morphology, with a similar proportion of insulin, glucagon and somatostatin 
immunostaining observed in islets of WT and FFAR2-/- mice (Figure 1a), as determined by Image J 
analysis of individual image acquisitions. Similarly, loss of FFAR2 did not induce any significant changes 
in the amplitude of glucose-induced insulin secretion from isolated islets (Figure 1b), nor in the islet 
insulin content (Figure 1c), and no differences in islet size or yield were identified during the isolation 
procedure. In addition, FFAR2 deletion was not associated with any changes in expression of the other 
ScFA receptor, FFAR3 in islets (Figure 1d). 
 
Acetate and propionate potentiate glucose-stimulated insulin secretion from mouse islets in a 
FFAR2-dependent manner. 
Quantification of dynamic insulin secretion from mouse islets revealed that both SA and SP reversibly 
potentiated glucose-induced insulin secretion in a FFAR2- dependent manner. Thus, islets responded 
within two minutes to exposure to 1mM SA (Figure 2a) or 1mM SP (Figure 2b) such that the plateau 
phase of secretion in response to 20mM glucose was significantly enhanced by both fatty acids. The 
effect of SA was of lower amplitude and less sustained than that of SP, which induced a potentiation 
that was maintained for the duration of exposure and readily reversible upon its removal. The 
requirement of FFAR2 for the stimulatory effects of SA and SP was evident from their inability to 
potentiate insulin release when islets isolated from FFAR2-/- mice were used (Figures 2a and 2b, open 
circles). 
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Effects of acetate and propionate on islet second messenger generation. 
We have previously shown that SP increases [Ca2+]i in human islets [5], consistent with Gq-mediated 
signalling. Microfluorimetry measurements were made from Fura-2-loaded mouse islet -cells, which 
were identified by their characteristic biphasic response to an elevation in extracellular glucose 
concentration (Figures 3a and 3b). These experiments indicated that SA elevated -cell [Ca2+]i, with a 
transient potentiation of the elevation induced by 20mM glucose (Figure 3a). This effect of SA was 
completely dependent on the presence of FFAR2, because it did not increase [Ca2+]i in islets from 
FFAR2-/- mice, whereas the response to 20mM glucose was not impaired by FFAR2 deletion (Figure 
3b). 
 
The potential contribution of Gi-mediated signalling in the effects of SA and SP in islets was 
investigated by the quantification of mouse islet cAMP levels by FRET. Elevations in islet cAMP were 
induced by exposure to 1M forskolin in the presence of the phosphodiesterase inhibitor IBMX, and 
the Gi-coupled 2-adrenergic agonist clonidine completely suppressed cAMP production in response 
to forksolin (Figure 3c). However, under the same conditions neither 1mM SA nor 1mM SP had any 
significant effects on islet cAMP generation, and no significant differences in cAMP levels were 
observed in the responses of islets from WT and FFAR2-/- mice (Figure 3c). 
 
As ScFAs may regulate intracellular signalling secondary to their mitochondrial metabolism their 
effects on islet ATP generation were also investigated. These experiments indicated that elevation in 
glucose concentration from 2mM to 20mM stimulated ATP levels, as expected (Figure 3d), but 1mM 
SA or SP did not elevate basal or glucose-stimulated ATP production. Similar to the experiments in 
which cAMP was quantified, deletion of FFAR2 did not influence glucose-induced ATP generation in 
mouse islets, and nor did it modify the levels of ATP observed in the presence of SA or SP (Figure 3d). 
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Acetate potentiates insulin secretion from human islets via PLC/PKC-dependent pathways, but does 
not activate Gi-coupled signalling. 
Our earlier experiments investigating ScFA signalling in human islets focused on the role of SP [5] so 
we extended these studies here to determine the concentration-dependent effects of the shorter 
ScFA, SA, on insulin secretion from isolated human islets, and the signalling pathways utilised. It can 
be seen from Figure 4a that SA stimulated a concentration-dependent reversible potentiation of 
glucose-induced insulin release, which was statistically significant at concentrations as low as 1μM SA 
(Figure 4b). We have previously reported that SP-induced insulin secretion from human islets involves 
the recruitment of PLC/PKC-dependent pathways [5]. To verify whether SA utilises similar signalling 
cascades to SP, isolated human islets were pre-perifused for 10 minutes with 10M of the PLC 
inhibitor U73122 (open circles) or vehicle (closed circles), and dynamic perifusion indicated that the 
potentiation of glucose-induced insulin secretion by 100M SA was lost following PLC inhibition 
(Figure 4c). In parallel experiments human islets were pre-incubated for 20 hours with PMA to deplete 
PKC [25] prior to perifusion. As shown in Figure 4d, 100M SA induced a large potentiation of insulin 
secretion in islets that had been pre-treated with vehicle (solid circles) or with the inactive phorbol 
ester PDD (open squares), and this secretory response to SA was significantly reduced after PKC 
depletion (open circles).  
 
The stimulation of insulin release from human islets by SA is in contrast to a previous report of its Gi-
mediated inhibition of glucose-stimulated insulin secretion from human islets in static incubations [8]. 
We therefore investigated whether SA acted via Gi in human islets by pre-treating them with 
100ng/mL PTX to ADP-ribosylate Gi and thus abolish signalling via this pathway. As can be seen from 
Figure 4e, PTX-treated islets (open circles) responded to SA with a similar profile to the vehicle-treated 
islets (closed circles), indicating that inhibition of Gi-dependent signalling did not unveil any further 
potentiation of insulin secretion by SA. Further demonstration that SA does not act via Gi in human 
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islets was evident from the lack of inhibitory effect of SA on intracellular cAMP levels (1M forskolin: 
120.811.9nM; +1mM SA: 144.87.6nM, p>0.2; +10M clonidine: 79.66.8nM, p<0.001, n=6). 
 
ScFAs protect islets from apoptosis 
The effects of ScFAs on isolated islets are not limited to improving their insulin secretory performance. 
Previously we established that overnight exposure of human islets to SP protects against both cytokine 
and palmitate-induced apoptosis [5], and we observed that SA also has an anti-apoptotic effect in 
human islets in the current study (Figure 5a). To determine whether ScFAs also reduce apoptosis in 
mouse islets, and the role of FFAR2 in this effect, apoptosis was induced in islets isolated from WT and 
FFAR2-/- mice by exposure to a cytokine cocktail (Figure 5b, black bars) or 0.5mM palmitate (Figure 5b, 
grey bars). Incubation of islets with SA or SP provided significant protection against the elevation in 
islet caspase 3/7 activities induced by cytokines or palmitate (Figure 5b, upper panel), and these anti-
apoptotic effects of the ScFAs were significantly reduced or abolished when the experiments were 
carried out using islets from FFAR2-/- mice (Figure 5b, lower panel). 
 
Discussion 
The beneficial effects of diets rich in fibre and fermentable carbohydrates on glucose homeostasis in 
humans has been evident for several years [1, 2, 5, 26-30], and it is now recognised that dietary 
fermentable precursors lead to elevations in SA and SP both in the colonic lumen and in the general 
circulation [5, 14]. The G-protein coupled receptor FFAR2 has been implicated in the effects of ScFAs 
in colonic L-cells, adipocytes and immune cells to promote secretion of incretin hormones, reduce 
lipolysis and regulate production of immune mediators [4, 27-32]. The demonstration of FFAR2 
involvement in GLP-1 and PYY secretion from the intestine suggests that beneficial effects of ScFAs on 
islets could be, at least in part, secondary to the indirect stimulatory and protective effects of these 
incretins on islet β-cells [27, 28, 33]. However, the presence of FFAR2 on mouse and human β-cells [4-
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7] supports a direct role in islets for those ScFAs originating from colonic fermentation of dietary fibre 
and undigested carbohydrates.  
 
Although FFAR2 and FFAR3 deletion is reported to improve glucose tolerance in obese mice [7], it has 
also been reported that FFAR2-/- mice fed a high fat diet show no changes in glucose tolerance [8] and 
that obese [6] and pregnant [9] FFAR2-/- mice develop glucose intolerance, so it is not clear from 
published studies whether FFAR2 improves or impairs glucose homeostasis. The observation that 
FFAR2-/- mice have reduced -cell mass at birth suggests a role for FFAR2 in -cell development, and 
the reduced -cell area was also observed in adulthood [11]. However, -cell proliferation is elevated 
in FFAR2-/- mice [11] and deletion of FFAR2 does not impair glucose tolerance in mice fed normal chow 
[6, 8, 9], suggesting that FFAR2 is not essential for normal glucose homeostasis. Consistent with this, 
our immunohistochemical analysis of islets from 8-10 week old FFAR2-/- mice and quantification of 
insulin secretion and content demonstrate that there was no impairment of functional -cell mass 
following FFAR2 deletion. Since in vivo measurements on global FFAR2-/- mice do not specifically 
identify the role of this receptor in regulating -cell function, in the current study we have used 
isolated mouse and human islets to identify direct functional effects of SA and SP, distinct from any 
influence of circulating mediators released from other cells expressing FFAR2.  
 
Our data with isolated islets build on our earlier study in which we demonstrated direct potentiation 
of glucose-induced insulin secretion from human islets by SP [5], and our use here of islets isolated 
from FFAR2-/- mice has now allowed us to identify that ScFAs directly stimulate insulin secretion and 
protect against apoptosis in a FFAR2-dependent manner. In addition, we have identified that SA and 
SP signal in mouse and human islets via stimulatory Gq-dependent pathways, such that they activate 
PLC and stimulate FFAR2-dependent elevation in [Ca2+]i. Furthermore, experiments in which islet PKC 
was down-regulated indicate that this kinase is important in mediating SA potentiation of insulin 
secretion, most likely secondary to PLC-mediated diacylglycerol generation and increased [Ca2+]i. 
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However, the stimulatory effects of SA on insulin release were not abolished following PKC depletion, 
implicating a PKC-independent mode of action, perhaps via another Ca2+-dependent pathway such as 
activation of Ca2+-calmodulin-dependent kinase II [34].  
 
The capacity of ScFAs to bind to and activate both FFAR2 and FFAR3 has led to some inconsistencies 
in published data, because FFAR3 couples only to Gi whereas FFAR2 couples to both Gi and Gq [14]. 
Inhibitory effects of ScFAs on insulin secretion have been reported, most likely a consequence of Gi-
mediated reductions in intracellular cAMP levels [7]. Our results indicate that ScFAs do not reduce 
cAMP production by mouse or human islets, and the effects of SA to potentiate insulin secretion were 
not modified by PTX-induced inactivation of Gi signalling in human islets. The data that we obtained 
with PTX treatment of human islets also indicate that its abolition of the cAMP inhibitory tone does 
not result in an increase in basal or glucose-stimulated insulin secretion, as is observed with PTX 
inactivation of Gi signalling in mouse islets [23]. The reasons for this difference is not clear, but these 
observations suggest that tonic cAMP inhibition is more important in mouse than human islets.  
 
It has recently become apparent that co-expression of FFAR2 and FFAR3 by cells can result in 
formation of FFAR2/FFAR3 heteromers in which ScFA-induced inhibition of cAMP generation is 
impaired and Ca2+ signalling is enhanced [35]. It is thus possible that FFAR2/FFAR3 heteromers in -
cells allow ScFAs to preferentially couple to PLC activation to promote stimulatory cascades.  
 
In addition to promoting insulin secretion we found that SA and SP also exerted anti-apoptotic actions 
in islets under both cytotoxic and lipotoxic conditions that mimic the physiological stresses to which 
islets are exposed during type 1 and type 2 diabetes. The use of islets from FFAR2-/- mice has allowed 
us to identify the important role of this receptor in transducing not only the stimulatory effects of SA 
and SP on insulin release, but also their protective effects against apoptotic stimuli. These data are in 
agreement with earlier reports that FFAR2 is required for the adaptive expansion of β-cell mass during 
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pregnancy [28], and that the loss of FFAR2 is linked to impaired islet mass and β-cell survival [29]. 
Nevertheless, more studies are needed to elucidate the intracellular pathways that are activated by 
FFAR2 to sustain islet viability and mass expansion. 
 
In conclusion, our work provides important data to support a re-evaluation of FFAR2 in mediating 
stimulatory effects of the ScFAs SA and SP in islets. The SA- and SP-induced reversible potentiation of 
glucose-induced insulin secretion and protection against apoptosis are typical of an effective therapy 
for type 2 diabetes, and the FFAR2-dependence of these effects suggest that FFAR2 represents a 
potential pharmacological candidate for the treatment of impaired glucose homeostasis and type 2 
diabetes. 
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Figure Legends 
 
Figure 1: Effects of FFAR2 deletion on islet physiological parameters. 
a) Islet hormone immunofluorescence in pancreas sections from WT (upper panel) and FFAR2-/- (lower 
panel) mice. Sections were co-stained for insulin (red) and glucagon (green) or insulin (red) and 
somatostatin (green), as indicated. Images are representative of 10-15 sections from each of 4 WT 
and 4 FFAR2-/- mice. 
b) Dynamic profiling of glucose-dependent insulin secretion from islets isolated from WT (solid circles) 
and FFAR2-/- (open circles) mice. Data are expressed as mean+SEM of 6 independent isolations, with 
4 independent replicates per experiment for each genotype. p>0.1: WT vs FFAR2-/-, insulin secretion. 
c) Insulin content of islets isolated from WT (white bar) and FFAR2-/- (black bar) mice. Data are 
expressed as mean+SEM of 3 independent isolations. p>0.1: WT vs FFAR2-/-, islet insulin content. 
d) Expression of FFAR3 mRNA in islets isolated from WT and FFAR2-/- mice relative to Gapdh mRNA. 
Data are expressed as mean+SEM of 4 independent isolations. p>0.1: WT vs FFAR2-/-, FFAR3 mRNA 
expression. 
 
Figure 2: Role of FFAR2 in sodium acetate and sodium propionate potentiation of glucose-induced 
insulin secretion from mouse islets. 
Dynamic profiling of sodium acetate (SA) (a) and sodium propionate (SP) (b) potentiation of glucose-
dependent insulin secretion from islets isolated from WT (solid circles) and FFAR2-/- (open circles) mice. 
Data are expressed as mean±SEM of n=8 experiments with 4 independent replicates per experiment 
for each genotype. p<0.0001: WT vs FFAR2-/-, insulin secretion in response to SA; **p<0.01: WT vs 
FFAR2-/-, insulin secretion in response to SP. 
 
Figure 3: Effects of sodium acetate and sodium propionate on generation of islet second messengers. 
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Dynamic profiling of the effects of sodium acetate (SA) on intracellular Ca2+ levels in dispersed islet 
cells from WT (a) and FFAR2-/- (b) mice. Data are expressed as mean±SEM of 26 WT cells and 31 FFAR2-
/- cells and the traces are representative of 4 independent experiments for each genotype.  
c) Cyclic AMP generation in islets isolated from WT (white bars) and FFAR2-/- (black bars) mice. Data 
are expressed as mean+SEM, n=6, representative of 3 independent experiments for each genotype. 
***p<0.001. 
d) ATP generation in islets isolated from WT (white bars) and FFAR2-/- (black bars) mice. Data are 
expressed as mean+SEM, n=4-6, representative of 4 independent experiments for each genotype. 
*p<0.05: ATP vs levels at 2mM glucose of the relative group. 
 
Figure 4: Sodium acetate reversibly potentiates insulin secretion from human islets via PLC- and 
PKC-dependent pathways. 
a) Dynamic profiling of insulin secretion from human islets exposed to different concentrations of 
sodium acetate (SA) in the presence of 20mM glucose. Data are expressed as mean±SEM of n=6 
independent experiments, with 4 replicates per SA concentration. 
b) Area under the curve (AUC) data were calculated for all perifusion conditions shown in panel a). 
**p<0.01, ***p<0.001, nsp>0.1: insulin secretion in response to SA vs control. 
c) Dynamic profiling of insulin secretion from human islets exposed to sodium acetate (SA) in the 
absence (solid circles) or presence (white circles) of the selective PLC inhibitor U73122. Data are 
expressed as mean±SEM of n=3 independent experiments, with 3 replicates per condition. p<0.05: 
control vs U73122, insulin secretion in response to SA. 
d) Dynamic profiling of insulin secretion from human islets incubated for 20 hours with 200nM PMA 
to down-regulate PKC (white circles), 200nM PDD, an inactive phorbol ester (open squares), or under 
standard culture conditions (solid circles). Data are expressed as mean±SEM of n=3 independent 
experiments, with 4 replicates per treatment. p<0.001: control vs PMA, insulin secretion in response 
to SA. 
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e) Dynamic profiling of glucose-dependent insulin secretion from human islets pre-exposed for 18 
hours to 100ng/mL PTX (open circles) or vehicle (solid circles). Data are expressed as mean±SEM of 
n=2 independent experiments, with 4 replicates per treatment. 
 
Figure 5: Sodium acetate and sodium propionate protect islets from apoptosis in a FFAR2-
dependent manner. 
a) Effects of sodium acetate (SA) on human islet apoptosis. Human islets were maintained for 20 hours 
in the presence of RPMI containing mixed cytokines (black bars) or cytokine-free RPMI (white bars) in 
the absence or presence of 1mM SA, and apoptosis was determined by luminescence assay of caspase 
3/7 activities. Data are expressed as mean+SEM, n=8, representative of 3 independent experiments. 
*p<0.05, **p<0.01. 
b) Contribution of FFAR2 to the anti-apoptotic effects of sodium acetate (SA) and sodium palmitate 
(SP). Islets isolated from WT (upper panel) or FFAR2-/- (lower panel) mice were maintained for 20 hours 
in the presence of RPMI containing mixed cytokines (black bars), sodium palmitate (grey bars) or RPMI 
containing 0.25% ethanol/0.5% BSA as a control for palmitate treatment (white bars) in the absence 
or presence of 1mM SA or SP. Apoptosis was determined as in (a) and data are expressed as 
mean+SEM of 6 independent experiments, each consisting of 6-8 replicates. **p<0.01, ***p<0.001, 
nsp>0.1. 
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